Evotec AG (EVTG.F): Results Of Pre-Clinical Studies Lead To Reduction In Revenues, Nevertheless Profitable And More Than EURO 90 M Cash For 2013 Confirmed
12/13/2013 9:09:29 AM
HAMBURG, Germany, Dec. 13, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it is adjusting its guidance regarding Group revenues.
Help employers find you! Check out all the jobs and post your resume.
comments powered by